Assessment of Attention Deficits in Adolescent Offspring Exposed to Maternal Type 1 Diabetes

PLoS One. 2017 Jan 10;12(1):e0169308. doi: 10.1371/journal.pone.0169308. eCollection 2017.

Abstract

Objective: The aim of this study was to examine the potential association between intrauterine exposure to maternal diabetes and attention deficits in the offspring.

Research design and methods: Adolescent offspring of a prospectively followed cohort of women with type 1 diabetes (n = 269) and a control group from the background population (n = 293) participated in a follow-up assessment in 2012-2013. We used scores from Conners Continuous Performance Test II to assess attention and based on a principal component analysis we evaluated scores on five different attention factors: focused attention, vigilance, hyperactivity/impulsivity, sustained attention and response style.

Results: A higher frequency of the exposed offspring had a parent/self-reported use of Attention Deficit Hyperactivity Disorder (ADHD) medication compared to the control group (2.2% vs. 0.0%, p = 0.01). Clinical significant differences between adolescents exposed to maternal diabetes and unexposed controls were not found in either single scores on Conners Continuous Performance Test or on any of the five attention factors identified.

Conclusions: Exposure to maternal type 1 diabetes did not seem to increase the risk of attention deficits in the adolescent offspring. However, a higher self-reported use of ADHD medication in the exposed group could suggest a difference in attention not revealed by the applied test.

MeSH terms

  • Adolescent
  • Adult
  • Attention
  • Attention Deficit Disorder with Hyperactivity / epidemiology*
  • Attention Deficit Disorder with Hyperactivity / etiology*
  • Denmark
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes, Gestational*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Maternal Exposure*
  • Pregnancy
  • Prenatal Exposure Delayed Effects*
  • Risk Factors
  • Young Adult

Grants and funding

The study was supported by the European Foundation for the Study of Diabetes; The Danish Ministry of Science, Innovation and Higher Education; Lundbeck Foundation; Danish Diabetes Academy; Beckett Foundation and Danielsen Foundation. HBN receives research support from Novo Nordisk, a commercial company. The sponsors of the study had no involvement in design, conduction or interpretation of the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.